Abstract

To investigate the effect of simvastatin on ventricular remodeling in rats with acute myocardial infarction through the transforming growth factor beta/SMAD signaling pathway. A rat acute myocardial infarction model was established by ligating the left anterior descending coronary artery as the acute myocardial infarction group; treated with low, medium and high doses (10 mg/kg, 20 mg/kg and 40 mg/kg) of simvastatin as acute myocardial infarction+simvastatin-low, acute myocardial infarction+simvastatin-medium, acute myocardial infarction+simvastatin-high groups. Set up another sham operation group (sham group). 4 w later, the rats' body weight, hemodynamic acute myocardial infarction indicators, and blood lipid levels were detected; quantitative reverse transcription polymerase chain reaction and Western blot were used to detect the expression of transforming growth factor beta 1, SMAD2/3 messenger ribonucleic acid and protein. Compared with the sham group, the left ventricular weight and left ventricular weight index of the rats were significantly increased (p<0.05); compared with the acute myocardial infarction group, simvastatin significantly reduced the left ventricular weight and left ventricular weight index of the rats (p<0.05). Compared with the sham group, the left ventricular systolic pressure of the acute myocardial infarction group was significantly increased, and the left ventricular end-diastolic pressure, +dp/dt_max and -dp/dt_max were significantly decreased (p<0.05); compared with the acute myocardial infarction group, simvastatin significantly reduced the rat left ventricular end-diastolic pressure, significantly increased left ventricular end-diastolic pressure, +dp/dt_max and -dp/dt_max (p<0.05). Compared with the sham group, the expression of transforming growth factor beta 1, SMAD2, SMAD3 messenger ribonucleic acid and protein in the acute myocardial infarction group was significantly increased (p<0.05); compared with the acute myocardial infarction group, simvastatin significantly reduced the expression of transforming growth factor beta 1, SMAD2, SMAD3 messenger ribonucleic acid and protein in the rat (p>0.05). Simvastatin can alleviate ventricular remodeling in acute myocardial infarction rats by inhibiting the transforming growth factor beta/SMAD signaling pathway.